Specialties – Page 109

Synergistic Effects of Metformin and Moderate FODMAP Diet in Improving Postprandial Glycemia and Gut Health in Prediabetes

By MedXY 08/17/2025

Combining metformin with a moderate FODMAP diet improves postprandial glucose control, enhances GLP-1 secretion, increases butyrate-producing gut bacteria, and reduces inflammation without worsening gastrointestinal side effects in prediabetic patients.

Dentistry news Otorhinolaryngology Specialties

A Single Injection to Regenerate Alveolar Bone: A Breakthrough in Non-Invasive Periodontitis Treatment

By MedXY 08/17/2025

A groundbreaking clinical trial demonstrates that dental pulp stem cell injections can safely and effectively regenerate alveolar bone in chronic periodontitis patients, offering a minimally invasive alternative to surgery.

news Public Health Specialties

Australia Report: Seven Major Challenges of Safe and Reliable Medical Artificial Intelligence in Legislation and Regulation

By MedXY 08/17/2025

This report outlines the challenges and recommendations for implementing AI in healthcare while ensuring safety and responsibility in Australia.

Cardiology Specialties

Long-Term Functional Recovery and Survival after VA-ECMO: Insights from a 26-Center Prospective Cohort Study

By MedXY 08/17/2025

A multicenter study reveals that 30% of adult VA-ECMO patients survive 12 months without new disability, with most disability developing within the first 6 months. Functional independence and employment improve by 12 months post-ECMO.

Cardiology Specialties

Decade-Long Insights into Deferred Versus Immediate Stenting in STEMI Patients: DANAMI-3-DEFER Trial Findings

By MedXY 08/17/2025

The 10-year DANAMI-3-DEFER study compared deferred stenting to immediate stenting in STEMI, showing no mortality benefit but reduced heart failure hospitalizations with deferred stenting.

Cardiology news Specialties

Early TAVR Benefits in Asymptomatic Severe Aortic Stenosis: Insights from Cardiac Biomarker Analysis in the EARLY TAVR Trial

By MedXY 08/17/2025

Cardiac biomarkers NT-proBNP and hs-cTnT predict higher risk in asymptomatic severe aortic stenosis, but early TAVR benefits patients regardless of biomarker levels, with greater relative advantage seen in those with lower biomarker concentrations.

Cardiology Diabetes & Endocrinology news Specialties

Oral Semaglutide in Type 2 Diabetes: Efficacy and Safety with and without SGLT2 Inhibitors from the SOUL Trial

By MedXY 08/17/2025

The SOUL trial demonstrates that oral semaglutide significantly reduces major cardiovascular events in type 2 diabetes patients, independently of concurrent SGLT2 inhibitor use, with a favorable safety profile.

Cardiology Specialties

Advancements in Transcatheter Edge-to-Edge Repair for Severe Tricuspid Regurgitation: Insights from the TRILUMINATE Pivotal Trial

By MedXY 08/17/2025

Transcatheter edge-to-edge repair (TEER) offers a safe, effective option to reduce tricuspid regurgitation severity, improve quality of life, and lower heart failure hospitalizations up to two years, including in patients with cardiac implantable electronic device leads.

Cardiology Specialties

Inclisiran Shows Promise for Adolescents with Homozygous Familial Hypercholesterolemia: Results from the ORION-13 Trial

By MedXY 08/17/2025

The ORION-13 trial demonstrates that inclisiran significantly lowers LDL cholesterol by 33.3% and is safe and well tolerated in adolescents with homozygous familial hypercholesterolemia, addressing an unmet pediatric treatment need.

Cardiology Clinical Updates General Surgery news Specialties

Renal Denervation Shows Sustained Blood Pressure Reduction and Safety Over 24 Months in SPYRAL HTN-ON MED Trial

By MedXY 08/17/2025

The SPYRAL HTN-ON MED trial demonstrates that renal denervation provides significant long-term reductions in both ambulatory and office systolic blood pressure with good safety, supporting its role in managing hypertension.

Cardiology news Specialties

Higher Risk of Major Gastrointestinal Bleeding with Edoxaban vs Warfarin After TAVR: Insights from the ENVISAGE-TAVI AF Trial

By MedXY 08/17/2025

The ENVISAGE-TAVI AF trial found that patients with atrial fibrillation undergoing TAVR had a higher incidence of major gastrointestinal bleeding when treated with edoxaban compared to warfarin, highlighting the importance of risk factor identification.

Cardiology Specialties

Edoxaban as a Safe and Effective Anticoagulant Early After Bioprosthetic Valve Replacement: Insights from the ENBALV Trial

By MedXY 08/17/2025

The ENBALV randomized trial demonstrates that edoxaban offers a potential safe and efficacious alternative to warfarin for anticoagulation within three months after surgical bioprosthetic valve replacement, with comparable thromboembolic event rates and a distinct safety profile.

Cardiology news Specialties

ADVANTAGE AF Phase 2: Evaluating Pulsed Field Ablation for Persistent Atrial Fibrillation Using Continuous ECG Monitoring

By MedXY 08/17/2025

The ADVANTAGE AF Phase 2 study demonstrates pulsed field ablation's safety and efficacy for persistent atrial fibrillation, introducing continuous cardiac monitoring to better assess arrhythmia burden and outcomes over one year.

Cardiology news Specialties

Optimizing Sedation for Pulsed-Field Ablation in Atrial Fibrillation: Results of the COOPERATIVE-PFA Trial

By MedXY 08/17/2025

This randomized trial compares sedation regimens for pulsed-field ablation in atrial fibrillation, finding remimazolam-ketamine deep analgosedation superior to propofol-opioid approaches in reducing hypoxemia and hypotension.

Cardiology Clinical Updates news Specialties

High-Dose Statins and Their Impact on the Progression of Small Abdominal Aortic Aneurysms: Insights from a 5-Year Danish Cohort Study

By MedXY 08/17/2025

This 5-year prospective cohort study reveals that high-dose statin therapy significantly slows abdominal aortic aneurysm growth and reduces the risks of repair, rupture, and death in men, suggesting benefits beyond traditional cardiovascular risk management.

news Rheumatology Specialties

Unraveling the Link Between Somatic JAK2V617F Mutation and Ascending Aortic Aneurysms: Evidence from a Large-Scale Cardiovascular Screening

By MedXY 08/17/2025

A multicenter Danish study reveals a strong independent association between somatic JAK2V617F mutation—especially its variant allele frequency—and risk of ascending aortic aneurysms, suggesting targeted screening strategies.

AI Clinical Updates Nephrology news Specialties

Evaluating Electronic Nudges to Enhance Guideline-Directed Therapy in Chronic Kidney Disease: Insights from the NUDGE-CKD Trial

By MedXY 08/16/2025

The NUDGE-CKD trial found that electronic letter-based nudges to patients with chronic kidney disease and their general practitioners did not significantly improve initiation of guideline-recommended medications over usual care.

Cardiology Clinical Updates news Specialties

Abelacimab vs. Rivaroxaban in Atrial Fibrillation Patients on Antiplatelet Therapy: Insights from the AZALEA-TIMI 71 Trial

By MedXY 08/16/2025

The AZALEA-TIMI 71 trial shows abelacimab, a novel factor XI inhibitor, reduces bleeding risk compared to rivaroxaban in atrial fibrillation patients on antiplatelet therapy, suggesting a safer anticoagulation alternative.

Cardiology Clinical Updates news Specialties

High-Risk Plaques in Non-Culprit Lesions: Comparative Outcomes After NSTEMI and STEMI

By MedXY 08/16/2025

This study examines the morphology of high-risk plaques in non-culprit coronary lesions among NSTEMI and STEMI patients and their impact on clinical outcomes, suggesting comparable prevalence of high-risk features but differing plaque characteristics between these groups.